Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTKWM86)

• DTT Name: Opioid receptor mu (MOP) DTT Info
• Gene Name: OPRM1

Molecule-Related Drug & Molecule List

23 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alfentanil	DMVO0UB	Anaesthesia	9A78.6	Approved	[1]
Alvimopan	DMHR8KW	Gastrointestinal disease	DE2Z	Approved	[2]
Anileridine	DMBAUED	Pain	MG30-MG3Z	Approved	[3]
Anileridine Hydrochloride	DMC128O	Pain	MG30-MG3Z	Approved	[4]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[5]
Diphenoxylate	DMO5SZX	Diarrhea	ME05.1	Approved	[6]
Eluxadoline	DMYZ0P1	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[7]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[8]
Hydrocodone	DMQ2JO5	Allergic rhinitis	CA08.0	Approved	[9]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[10]
Levomethadyl Acetate	DM06HG5	Opioid dependence	6C43.2Z	Approved	[11]
Levopropoxyphene Napsylate Anhydrous	DMECB4H	Cough	MD12	Approved	[4]
Methadyl Acetate	DMIRMVB	Opioid dependence	6C43.2Z	Approved	[12]
Methylnaltrexone bromide	DMZTGN2	Opioid-induced constipation	DB32.1	Approved	[13]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[14]
Naldemedine Tosylate	DMGD3YH	Opioid-induced constipation	DB32.1	Approved	[15]
Nalfurafine hcl	DMA9DHW	Uremic pruritus	EC90.10	Approved	[16]
Naloxegol	DML0B41	Opioid-induced constipation	DB32.1	Approved	[17]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[18]
Oxycodone	DMXLKHV	Osteoarthritis	FA00-FA05	Approved	[19]
Propoxyphene Hydrochloride	DMMSOLA	Pain	MG30-MG3Z	Approved	[20]
Remifentanil	DMZTXCH	Anaesthesia	9A78.6	Approved	[21]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[13]

16 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GRT-6005	DMHN3PG	Diabetic neuropathy	8C0Z	Phase 3	[22]
Morphine-6-glucuronide	DMPVW6H	Pain	MG30-MG3Z	Phase 3	[23]
NKTR-181	DM45DS8	Chronic low back pain	MG30.02	Phase 3	[24]
ALKS33	DMF3QN1	Alcohol dependence	6C40.2	Phase 2	[25]
Carfentanil	DM7ADGX	N. A.	N. A.	Phase 2	[26]
Met-enkephalin	DMSZFTP	Pain	MG30-MG3Z	Phase 2	[27]
OPNT001	DMYG1ZQ	Eating disorder	6B82	Phase 2	[28]
ORP-101	DMSH20P	Irritable bowel syndrome	DD91.0	Phase 2	[29]
TD-1211	DMTJMK5	Opioid-induced constipation	DB32.1	Phase 2	[30]
AIKO-150	DMW9ZFS	Opioid dependence	6C43.2Z	Phase 1	[10]
Cyt-1010	DMTV09A	Pain	MG30-MG3Z	Phase 1	[31]
GSK1521498	DM2L7TH	Obesity	5B81	Phase 1	[32]
MCP-201	DMW9YOJ	Pain	MG30-MG3Z	Phase 1	[33]
NOCICEPTIN	DMUPA7C	Headache	8A80-8A84	Phase 1	[34]
SALVINORIN A	DMJ3HQY	Cerebral vasospasm	BA85.Z	Phase 1	[35]
TRV734	DMHD8CF	Chronic pain	MG30	Phase 1	[36]

19 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ADL-5945	DMQM54P	Constipation	DD91.1	Discontinued in Phase 2	[37]
BCH-2687	DM6ANFC	Pain	MG30-MG3Z	Discontinued in Phase 2	[38]
DPI-3290	DMKGXT2	Pain	MG30-MG3Z	Discontinued in Phase 2	[39]
Dynorphin a	DMT2WVP	N. A.	N. A.	Discontinued in Phase 2	[40]
Frakefamide	DMTRBU4	Pain	MG30-MG3Z	Discontinued in Phase 2	[41]
MIRFENTANIL HYDROCHLORIDE	DMT6IUR	Pain	MG30-MG3Z	Discontinued in Phase 2	[42]
Transdur-sufentanil	DMX32RC	Pain	MG30-MG3Z	Discontinued in Phase 2	[43]
TREFENTANIL HYDROCHLORIDE	DME85Z9	Pain	MG30-MG3Z	Discontinued in Phase 2	[44]
ADL-7445	DML1AUZ	Constipation	DD91.1	Discontinued in Phase 1	[37]
KN-203	DM37IH5	Urinary incontinence	MF50.2	Discontinued in Phase 1	[45]
VP004	DMXK8FQ	Substance use disorder	6C4Z	Discontinued in Phase 1	[46]
443C81	DMQ4X7Y	Asthma	CA23	Terminated	[49]
BCH-150	DMNH9A6	Gastrointestinal disease	DE2Z	Terminated	[50]
BIPHALIN	DMKNS10	N. A.	N. A.	Terminated	[51]
DBO-11	DM8GHT2	Cancer related pain	MG30	Terminated	[23]
DBO-17	DMFJ3UW	Cancer related pain	MG30	Terminated	[23]
Sameridine	DMEN6YO	Pain	MG30-MG3Z	Terminated	[52]
SB-213698	DM58PKG	N. A.	N. A.	Terminated	[53]
SNF-9007	DM4CNM9	N. A.	N. A.	Terminated	[54]

2 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GNTI	DMTJRLU	Obesity	5B81	Preclinical	[47]
LY-25582	DM2N637	Obesity	5B81	Preclinical	[48]

449 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[55]
(+/-)-TRANS-U-50488 METHANESULFONATE	DMM2QOX	Discovery agent	N.A.	Investigative	[56]
(-)-cyclorphan	DMC8WS4	Discovery agent	N.A.	Investigative	[57]
(-)-eseroline	DMJD34Q	Discovery agent	N.A.	Investigative	[56]
(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)	DMSCQ64	Discovery agent	N.A.	Investigative	[58]
1,10-bis-(Dmt-Tic-amino)decane	DM9UGFQ	Discovery agent	N.A.	Investigative	[59]
1,4-bis-(Dmt-Tic-amino)butane	DMLBHXN	Discovery agent	N.A.	Investigative	[59]
1,6-bis-(Dmt-Tic-amino)hexane	DMRG2CU	Discovery agent	N.A.	Investigative	[59]
1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane	DMMUZK9	Discovery agent	N.A.	Investigative	[59]
1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol	DMOR9EK	Discovery agent	N.A.	Investigative	[60]
1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol	DMV3FSH	Discovery agent	N.A.	Investigative	[60]
1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol	DMLYO8P	Discovery agent	N.A.	Investigative	[60]
1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol	DMTANPG	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol	DMWHMNY	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol	DMXZFPB	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol	DM1QYS8	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol	DMIT7SH	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol	DM0BQYX	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol	DMWYG8K	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol	DME0BJD	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol	DMRNZD6	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol	DMXT894	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol	DMJDUM5	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(furan-2-yl)piperidin-4-ol	DMMB2GV	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol	DMJ8F60	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol	DMNOZR2	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-benzylpiperidin-4-ol	DMVBR36	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-butylpiperidin-4-ol	DMRN7SC	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-cyclohexylpiperidin-4-ol	DMZVSYD	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-cyclopropylpiperidin-4-ol	DMM94Y2	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-ethoxy-4-phenylpiperidine	DM6PIL2	Discovery agent	N.A.	Investigative	[60]
1-benzhydryl-4-hexylpiperidin-4-ol	DMUK95S	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-isopropylpiperidin-4-ol	DMGYCQ3	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-m-tolylpiperidin-4-ol	DMVJH1S	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-methoxy-4-phenylpiperidine	DMBG0N8	Discovery agent	N.A.	Investigative	[60]
1-benzhydryl-4-o-tolylpiperidin-4-ol	DMVUMSF	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-p-tolylpiperidin-4-ol	DM679RC	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-phenyl-4-propoxypiperidine	DMEB968	Discovery agent	N.A.	Investigative	[60]
1-benzhydryl-4-phenylpiperidin-4-ol	DM7KU1X	Discovery agent	N.A.	Investigative	[62]
1-benzhydryl-4-tert-butylpiperidin-4-ol	DMM5DTF	Discovery agent	N.A.	Investigative	[61]
1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol	DMLRS8I	Discovery agent	N.A.	Investigative	[63]
1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol	DMB1NF0	Discovery agent	N.A.	Investigative	[63]
14-O-phenylpropylnaltrexone	DMI7LXH	Discovery agent	N.A.	Investigative	[64]
17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine	DMUQWPZ	Discovery agent	N.A.	Investigative	[65]
17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine	DM174HN	Discovery agent	N.A.	Investigative	[65]
17-methyl-4'-methyldihydromorphinone	DMMEB64	Discovery agent	N.A.	Investigative	[66]
17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate	DMI4WCQ	Discovery agent	N.A.	Investigative	[65]
2-(2-methylquinolin-4-ylamino)-N-phenylacetamide	DMW75IF	Discovery agent	N.A.	Investigative	[67]
2-Benzylaminomethyl-3-hydroxymorphinan	DM6EMGJ	Discovery agent	N.A.	Investigative	[65]
2-Hydroxymethyl-3-hydroxymorphinan	DM4LMPD	Discovery agent	N.A.	Investigative	[65]
3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone	DMWTP7Y	Discovery agent	N.A.	Investigative	[59]
3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone	DM2Y4A6	Discovery agent	N.A.	Investigative	[59]
3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone	DMJR983	Discovery agent	N.A.	Investigative	[59]
3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone	DMEQBS3	Discovery agent	N.A.	Investigative	[59]
3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole	DM2YKHI	Discovery agent	N.A.	Investigative	[68]
3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol	DM1DQGJ	Discovery agent	N.A.	Investigative	[69]
3-desoxy-3-carboxamidonaltrexone	DMBNA0V	Discovery agent	N.A.	Investigative	[25]
3-Methylfentanyl	DMX71N9	Discovery agent	N.A.	Investigative	[70]
3-Methylthiofentanyl	DMC153X	Discovery agent	N.A.	Investigative	[71]
4-(4-((phenethylamino)methyl)phenoxy)benzamide	DM0QRJ3	Discovery agent	N.A.	Investigative	[72]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[73]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide	DM0XDG6	Discovery agent	N.A.	Investigative	[74]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol	DM8ZRAE	Discovery agent	N.A.	Investigative	[75]
4-phenyl-1-(1-phenylbutyl)piperidin-4-ol	DMVCIJB	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(1-phenylethyl)piperidin-4-ol	DM6EFLV	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(1-phenylheptyl)piperidin-4-ol	DMISTXQ	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(1-phenylhexyl)piperidin-4-ol	DM1GRWY	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(1-phenylpentyl)piperidin-4-ol	DMZQ7DP	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(1-phenylpropyl)piperidin-4-ol	DMALIQ8	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol	DMFV0JC	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol	DM2MPWC	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol	DM5R6T4	Discovery agent	N.A.	Investigative	[60]
5-(4-((phenethylamino)methyl)phenoxy)picolinamide	DMZYE8W	Discovery agent	N.A.	Investigative	[72]
6-(2-benzylisoindolin-5-yloxy)nicotinamide	DMUD2R9	Discovery agent	N.A.	Investigative	[48]
6-(2-phenethylisoindolin-5-yloxy)nicotinamide	DMQOJBN	Discovery agent	N.A.	Investigative	[48]
6-(4-((benzylamino)methyl)phenoxy)nicotinamide	DMEM1BA	Discovery agent	N.A.	Investigative	[72]
6-(4-((phenethylamino)methyl)phenoxy)nicotinamide	DM9VD4W	Discovery agent	N.A.	Investigative	[48]
6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide	DMDKOWP	Discovery agent	N.A.	Investigative	[48]
6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide	DMOSDM2	Discovery agent	N.A.	Investigative	[72]
6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide	DMDTMB7	Discovery agent	N.A.	Investigative	[72]
6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol	DMYMJHF	Discovery agent	N.A.	Investigative	[76]
6-desoxonaltrexone	DMGZQNS	Discovery agent	N.A.	Investigative	[25]
6beta-naltrexol HCl	DMZ8PBE	Discovery agent	N.A.	Investigative	[77]
8-azabicyclo[3.2.1]octan-3-yloxy-benzamide	DMQMSZR	Discovery agent	N.A.	Investigative	[78]
8-carboxamidocyclazocine	DMD18V5	Discovery agent	N.A.	Investigative	[79]
Ac-D-pro-L-Phe-D-trp-L-Phe-NH2	DMVDH4I	Discovery agent	N.A.	Investigative	[80]
Ac-L-Phe-D-trp-L-Phe-D-pro-NH2	DMKVU8P	Discovery agent	N.A.	Investigative	[80]
Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG	DM512OP	Discovery agent	N.A.	Investigative	[81]
Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG	DMAHQIV	Discovery agent	N.A.	Investigative	[81]
Ac-RYYRIK-K-(NH2)-YAFGYPS	DM2ND3U	Discovery agent	N.A.	Investigative	[81]
Ac-RYYRIK-K-(NH2)-YRFB	DMNA3F4	Discovery agent	N.A.	Investigative	[81]
Ac-YGGFL-NH2	DMC0TU5	Discovery agent	N.A.	Investigative	[82]
ADC-5510	DMV761D	Movement disorder	8A07-8A0Z	Investigative	[19]
AIKO-151	DMUQ6XH	Opioid dependence	6C43.2Z	Investigative	[19]
AIKO-152	DML5Y1Q	Opioid dependence	6C43.2Z	Investigative	[19]
AKUAMMINE	DM8DYWN	Discovery agent	N.A.	Investigative	[56]
AMINOFENTANYL	DM7Y6AL	Discovery agent	N.A.	Investigative	[83]
Antanal 1	DMGDZ6Q	Discovery agent	N.A.	Investigative	[84]
Antanal 2	DMZSUHY	Discovery agent	N.A.	Investigative	[84]
Benzyl derivative of M6G	DMX8W4G	Discovery agent	N.A.	Investigative	[85]
Beta-endorphin	DM7XC6B	Discovery agent	N.A.	Investigative	[86]
Beta-funaltrexamine	DMJORFK	Discovery agent	N.A.	Investigative	[87]
Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate	DM0WKNI	Discovery agent	N.A.	Investigative	[57]
BREMAZOCINE	DM3EIBU	Discovery agent	N.A.	Investigative	[88]
BUTORPHAN	DM82KPQ	Discovery agent	N.A.	Investigative	[89]
C6S	DM4LIHQ	Discovery agent	N.A.	Investigative	[90]
CARBOXYFENTANYL	DMI7Q61	Discovery agent	N.A.	Investigative	[91]
Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	DMQUB19	Discovery agent	N.A.	Investigative	[92]
Clocinnamox	DMZLMJH	Discovery agent	N.A.	Investigative	[64]
CODEINONE	DM08WPL	Discovery agent	N.A.	Investigative	[93]
CTAP	DMLON9K	Discovery agent	N.A.	Investigative	[94]
CTOP	DM7VAJX	Discovery agent	N.A.	Investigative	[95]
CYCLAZOCINE	DMC6DAZ	Discovery agent	N.A.	Investigative	[89]
CYCLORPHAN	DMB1U8V	Discovery agent	N.A.	Investigative	[89]
CYPRODIME	DMJXCVA	Discovery agent	N.A.	Investigative	[96]
C[L-Ala-D-pro-L-Phe-D-trp]	DMHXTWK	Discovery agent	N.A.	Investigative	[80]
C[L-mTyr-D-pro-L-Phe-D-trp]	DMNHSR0	Discovery agent	N.A.	Investigative	[80]
C[L-Phe-D-pro-L-mTyr-D-trp]	DM82ZOM	Discovery agent	N.A.	Investigative	[80]
C[L-Phe-D-pro-L-Phe-D-trp]	DM0NTU5	Discovery agent	N.A.	Investigative	[80]
C[L-Phe-D-pro-L-Phe-L-trp]	DMCY4L0	Discovery agent	N.A.	Investigative	[80]
C[L-Phe-D-pro-L-Tyr(OMe)-D-trp]	DM4M3OP	Discovery agent	N.A.	Investigative	[80]
C[L-Phe-D-pro-L-Tyr-D-trp]	DMADSBT	Discovery agent	N.A.	Investigative	[80]
C[L-Tyr(OMe)-D-pro-L-Phe-D-trp]	DMLB6UA	Discovery agent	N.A.	Investigative	[80]
C[L-Tyr-D-pro-L-Phe-D-trp]	DM7OIY8	Discovery agent	N.A.	Investigative	[80]
D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2	DMUJC97	Discovery agent	N.A.	Investigative	[97]
D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)	DM2EFLA	Discovery agent	N.A.	Investigative	[97]
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)	DMPQHRC	Discovery agent	N.A.	Investigative	[97]
D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2	DMMXA5K	Discovery agent	N.A.	Investigative	[97]
DADLE	DMRM0OW	Discovery agent	N.A.	Investigative	[98]
DAMGO	DMS1DVA	Discovery agent	N.A.	Investigative	[99]
DC6S	DMX9FOB	Discovery agent	N.A.	Investigative	[90]
Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	DMU287Q	Discovery agent	N.A.	Investigative	[100]
DELTORPHIN	DMHOT9P	Discovery agent	N.A.	Investigative	[101]
DELTORPHIN-II	DM9ZWRK	Discovery agent	N.A.	Investigative	[102]
Deprotected cogener of M6G	DMH340E	Discovery agent	N.A.	Investigative	[85]
DERMORPHIN	DMCYQHO	Discovery agent	N.A.	Investigative	[81]
Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	DMSN87T	Discovery agent	N.A.	Investigative	[100]
DIHYDROAKUAMMINE	DMW1ALX	Discovery agent	N.A.	Investigative	[56]
Dihydromorphine	DM4TR0D	Discovery agent	N.A.	Investigative	[103]
Dimepheptanol	DMRMHE8	Discovery agent	N.A.	Investigative	[76]
Dimethylthiambutene	DM7EKAF	Discovery agent	N.A.	Investigative	[104]
Diprenorphine	DMIXPU6	Discovery agent	N.A.	Investigative	[105]
DM3A6S	DM7YXKL	Discovery agent	N.A.	Investigative	[90]
DM3B6S	DML68UF	Discovery agent	N.A.	Investigative	[90]
DM6S	DMAJ0Q8	Discovery agent	N.A.	Investigative	[90]
Dmt-Pro-3,5Dmp-Phe-NH2	DM5WEFK	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Dmp-Phe-NH2	DMGUIR1	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Dmt-Phe-NH2	DM4VEU2	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Emp-Phe-NH2	DM06VGY	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Imp-Phe-NH2	DMXUI1J	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Mmp-Phe-NH2	DM78PFN	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Phe-D-1-Nal-NH2	DM0VCWA	Discovery agent	N.A.	Investigative	[107]
Dmt-Pro-Phe-D-2-Nal-NH2	DMRJVE8	Discovery agent	N.A.	Investigative	[107]
Dmt-Pro-Phe-Phe-NH2	DMM8BIE	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Tmp-Phe-NH2	DMEMQAK	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Trp-D-2-Nal-NH2	DMKEV5U	Discovery agent	N.A.	Investigative	[107]
Dmt-Sar-Phe-D-2-Nal-NH	DMHRT0F	Discovery agent	N.A.	Investigative	[108]
DPDPE	DMIRSNA	Discovery agent	N.A.	Investigative	[99]
DSLET	DMSTOB0	Discovery agent	N.A.	Investigative	[19]
dynorphin B	DMSPVLM	Discovery agent	N.A.	Investigative	[19]
Dynorphin(1-8)	DMM92LG	Discovery agent	N.A.	Investigative	[109]
ELAEOCARPENINE	DMRHSCQ	Discovery agent	N.A.	Investigative	[110]
ENDOMORPHIN 2	DMOQWBU	Discovery agent	N.A.	Investigative	[111]
ENDOMORPHIN-1	DMBJUEM	Discovery agent	N.A.	Investigative	[112]
Endomorphins	DMI2RQS	Inflammation	1A00-CA43.1	Investigative	[19]
ethylketocyclazocine	DM9YRCU	Discovery agent	N.A.	Investigative	[19]
Ethylmorphine	DM0YROF	Discovery agent	N.A.	Investigative	[113]
ETONITAZENE	DMFR1SE	Discovery agent	N.A.	Investigative	[114]
Etorphine	DM79YZN	Discovery agent	N.A.	Investigative	[115]
FALCARINDIOL	DMLOV18	Discovery agent	N.A.	Investigative	[116]
FLUPERAMIDE	DMEGL84	Discovery agent	N.A.	Investigative	[117]
H-2',6'-dimethyltyrosine-Tic-OH	DMYOADQ	N. A.	N. A.	Investigative	[118]
H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH	DM7IEU2	Discovery agent	N.A.	Investigative	[118]
H-Aba-ala-Gly-Phe-leu-OH	DM61G0I	Discovery agent	N.A.	Investigative	[27]
H-Aba-ala-Gly-Phe-Met-OH	DMKD94Q	Discovery agent	N.A.	Investigative	[27]
H-Aba-Gly-Gly-Phe-Leu-OH	DMH1L3P	Discovery agent	N.A.	Investigative	[27]
H-Aba-ser-Gly-Phe-Leu-Thr-OH	DMFE3J4	Discovery agent	N.A.	Investigative	[27]
H-Apa-ala-Gly-Phe-leu-OH	DM5SUYP	Discovery agent	N.A.	Investigative	[27]
H-Cdp-ala-Gly-Phe-leu-OH	DMV751G	Discovery agent	N.A.	Investigative	[27]
H-Cdp-Gly-Gly-Phe-Leu-OH	DMVEB8C	Discovery agent	N.A.	Investigative	[27]
H-Cdp-ser-Gly-Phe-Leu-Thr-OH	DMCDLTV	Discovery agent	N.A.	Investigative	[27]
H-Cpa-Gly-Gly-Phe-Met-NH2	DMU6PV8	Discovery agent	N.A.	Investigative	[27]
H-Cpa-Gly-Gly-Phe-Met-OH	DM154G2	Discovery agent	N.A.	Investigative	[27]
H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	DMY4QE6	Discovery agent	N.A.	Investigative	[119]
H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	DM8GC36	Discovery agent	N.A.	Investigative	[119]
H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	DMNAE6J	Discovery agent	N.A.	Investigative	[119]
H-Dmt-Aba-Gly-NH-CH2-Bid	DM9WJZK	Discovery agent	N.A.	Investigative	[120]
H-Dmt-Aba-Gly-NH-CH2-Ph	DM61CMS	Discovery agent	N.A.	Investigative	[120]
H-Dmt-Aba-Gly-NH-Ph	DMCQYIJ	Discovery agent	N.A.	Investigative	[120]
H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2	DMHK70B	Discovery agent	N.A.	Investigative	[121]
H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH	DMM9EPQ	Discovery agent	N.A.	Investigative	[121]
H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2	DM1ZDJ6	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH	DMC3APN	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2	DMY97TN	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH	DMGPAM0	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2	DMOI1U5	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH	DMZBFJ5	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2	DMNS1GX	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH	DMM9TUR	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-Asp-N(Me)-Ph	DM4JP8L	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Asp-NH-Bzl	DMBKOJG	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Asp-NH-Ph	DM3W9FQ	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-D-Asp-N(Me)-Ph	DM483BG	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-D-Asp-NH-Ph	DMUG7X1	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)	DMQSRPD	Discovery agent	N.A.	Investigative	[58]
H-Dmt-Tic-Glu-NH-(CH2)5-NH2	DMF52SH	Discovery agent	N.A.	Investigative	[124]
H-Dmt-Tic-Glu-NH2	DM8A573	Discovery agent	N.A.	Investigative	[124]
H-Dmt-Tic-Gly-N(Me)-Ph	DMHYKBC	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Gly-NH-Bzl	DMM39YW	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Gly-NH-CH2-Bid	DMH6JOU	Discovery agent	N.A.	Investigative	[120]
H-Dmt-Tic-Gly-NH-Ph	DMIZ28H	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph	DM2TY43	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-Lys(Ac)-NH-Ph	DMZH9P5	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-Lys(Z)-NH-CH2-Ph	DMP8HFA	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-Lys(Z)-NH-Ph	DMBXGLA	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-Lys-NH-CH2-Ph	DMDJ9PE	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-Lys-NH-Ph	DMT3Y6E	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H	DMMJ9YN	Discovery agent	N.A.	Investigative	[126]
H-Dmt-Tic-NH-(CH2)6-NH-Phe-H	DM0BGNE	Discovery agent	N.A.	Investigative	[126]
H-Dmt-Tic-NH-(CH2)6-NH-Tic-H	DMQ586T	Discovery agent	N.A.	Investigative	[126]
H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid	DMAU2H6	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid	DM5TZ1J	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me)	DMIDLPT	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me)	DMNEAQ9	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-NH-CH2-Boa	DM4IUCW	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH2-Bta	DMZ8C0U	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH2-CH2-NH2	DMYJAW4	Discovery agent	N.A.	Investigative	[128]
H-Dmt-Tic-NH-CH2-Imid	DMJ2F8M	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH2-ImidPh	DMKGIQJ	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH2-Indl	DMNY3A1	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH2-Indn	DMZWUFK	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid	DM8PJ92	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid	DMQ4ILK	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid	DMQEDP5	Discovery agent	N.A.	Investigative	[125]
H-mCpa-ala-Gly-Phe-leu-OH	DM17QMV	Discovery agent	N.A.	Investigative	[27]
H-mCpa-ser-Gly-Phe-Leu-Thr-OH	DM8OUHV	Discovery agent	N.A.	Investigative	[27]
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH	DMA2CZL	Discovery agent	N.A.	Investigative	[92]
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2	DM48XV0	Discovery agent	N.A.	Investigative	[129]
H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2	DMXPJHB	Discovery agent	N.A.	Investigative	[129]
H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2	DM7QAES	Discovery agent	N.A.	Investigative	[129]
H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2	DMZSTL5	Discovery agent	N.A.	Investigative	[129]
H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2	DMI7CR9	Discovery agent	N.A.	Investigative	[130]
H-Tyr-c[D-Orn-Aic-Glu]-NH2	DMOTI0P	Discovery agent	N.A.	Investigative	[130]
H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2	DMN2AQO	Discovery agent	N.A.	Investigative	[131]
H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2	DM6ZHWS	Discovery agent	N.A.	Investigative	[131]
H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2	DMDF9AS	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac	DM4VBDW	Discovery agent	N.A.	Investigative	[133]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H	DM0J8P6	Discovery agent	N.A.	Investigative	[134]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo	DMW50ZQ	Discovery agent	N.A.	Investigative	[134]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H	DMF82C1	Discovery agent	N.A.	Investigative	[134]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc	DM6UWKL	Discovery agent	N.A.	Investigative	[133]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H	DMSXD63	Discovery agent	N.A.	Investigative	[133]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac	DMRUD37	Discovery agent	N.A.	Investigative	[133]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc	DMIPXCZ	Discovery agent	N.A.	Investigative	[133]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H	DMFSKDM	Discovery agent	N.A.	Investigative	[134]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2	DM2K16M	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl	DMRE4ZI	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2	DM1ESMZ	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl	DM56KDV	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl	DMH3YKR	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2	DMSX8CH	Discovery agent	N.A.	Investigative	[131]
H-Tyr-Gly-Gly-Phe-Met-NH2	DM6D0ZS	Discovery agent	N.A.	Investigative	[27]
H-Tyr-Pro-Ala-Phe-NH2	DMP0CRD	Discovery agent	N.A.	Investigative	[82]
H-Tyr-Pro-Dap(6DMN)-Phe-NH2	DMQUNGC	Discovery agent	N.A.	Investigative	[58]
H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2	DM326GJ	Discovery agent	N.A.	Investigative	[58]
H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H	DMXQUKJ	Discovery agent	N.A.	Investigative	[128]
H-Tyr-Tic-Cha-Phe-OH	DM1VFLG	Discovery agent	N.A.	Investigative	[122]
H-Tyr-Tic-Phe-Phe-OH	DMI0U87	Discovery agent	N.A.	Investigative	[122]
HERKINORIN	DMJXBWV	Discovery agent	N.A.	Investigative	[35]
HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2	DM25KZE	Discovery agent	N.A.	Investigative	[135]
ICI-199441	DMEWZ80	Discovery agent	N.A.	Investigative	[136]
KETOCYCLAZOCINE	DM0RC8M	Discovery agent	N.A.	Investigative	[137]
KIN-3031	DMHEOBY	Pain	MG30-MG3Z	Investigative	[19]
KIN-4044	DMO8JQM	Non-small-cell lung cancer	2C25.Y	Investigative	[19]
KNT-5	DMZF3E9	Discovery agent	N.A.	Investigative	[138]
KNT-62	DM9M5HC	Discovery agent	N.A.	Investigative	[16]
KNT-63	DM0U5N9	Discovery agent	N.A.	Investigative	[16]
KRP-100	DMJX9E1	Discovery agent	N.A.	Investigative	[19]
KRP-110	DME9HZC	Constipation	DD91.1	Investigative	[19]
Leucine-enkephalin	DMT2CZK	Discovery agent	N.A.	Investigative	[109]
LOFENTANIL	DMR2WQE	Discovery agent	N.A.	Investigative	[139]
M3A6S	DMJK1RE	Discovery agent	N.A.	Investigative	[90]
M3B6S	DMAHGBF	Discovery agent	N.A.	Investigative	[90]
M3IBu6S	DM0UOF1	Discovery agent	N.A.	Investigative	[90]
M3P6S	DMXT87E	Discovery agent	N.A.	Investigative	[90]
M3Pr6S	DMMC8RN	Discovery agent	N.A.	Investigative	[90]
M3S	DMWADOY	Discovery agent	N.A.	Investigative	[90]
M6G thiosaccharide analogue	DMRB4YV	Discovery agent	N.A.	Investigative	[85]
M6S	DMFCUN4	Discovery agent	N.A.	Investigative	[90]
MC-CAM	DMAHN4L	Discovery agent	N.A.	Investigative	[140]
MCL-117	DMQIGZ7	Discovery agent	N.A.	Investigative	[57]
MCL-139	DMQ1BDZ	Discovery agent	N.A.	Investigative	[57]
MCL-144	DMW7ZF8	Discovery agent	N.A.	Investigative	[141]
MCL-145	DMJXU67	Discovery agent	N.A.	Investigative	[57]
MCL-147	DMH5SMT	Discovery agent	N.A.	Investigative	[142]
MCL-149	DMTWY94	Discovery agent	N.A.	Investigative	[142]
MCL-153	DMCPW5F	Discovery agent	N.A.	Investigative	[143]
MCL-154	DM3PIHV	Discovery agent	N.A.	Investigative	[143]
MCL-182	DM39YW1	Discovery agent	N.A.	Investigative	[142]
MCL-183	DMVR51Z	Discovery agent	N.A.	Investigative	[142]
MCL-428	DMXBHE4	Discovery agent	N.A.	Investigative	[144]
MCL-429	DM1XH04	Discovery agent	N.A.	Investigative	[144]
MCL-431	DMISHCW	Discovery agent	N.A.	Investigative	[144]
MCL-432	DMPOFAR	Discovery agent	N.A.	Investigative	[144]
MCL-433	DMD3OAQ	Discovery agent	N.A.	Investigative	[144]
MCL-434	DMR31VO	Discovery agent	N.A.	Investigative	[144]
MCL-435	DMLSYD9	Discovery agent	N.A.	Investigative	[144]
MCL-443	DM8LTQ4	Discovery agent	N.A.	Investigative	[144]
MCL-444	DM8HALS	Discovery agent	N.A.	Investigative	[144]
MCL-445	DMR2K4F	Discovery agent	N.A.	Investigative	[142]
MCL-446	DMXF73G	Discovery agent	N.A.	Investigative	[142]
MCL-447	DMSTGNH	Discovery agent	N.A.	Investigative	[142]
MCL-448	DMSJGA9	Discovery agent	N.A.	Investigative	[142]
MCL-449	DMQ890N	Discovery agent	N.A.	Investigative	[144]
MCL-450	DM7I6U8	Discovery agent	N.A.	Investigative	[145]
MCL-451	DMP523A	Discovery agent	N.A.	Investigative	[145]
MCL-457	DMORMGU	Discovery agent	N.A.	Investigative	[142]
MCL-458	DMZN93Y	Discovery agent	N.A.	Investigative	[142]
METAZOCINE	DMB6T23	Discovery agent	N.A.	Investigative	[146]
MM3A6S	DMB74MS	Discovery agent	N.A.	Investigative	[90]
MM3B6S	DM9PGQI	Discovery agent	N.A.	Investigative	[90]
MORPHICEPTIN	DM9A1RY	Discovery agent	N.A.	Investigative	[111]
MORPHINONE	DM9LQIA	Discovery agent	N.A.	Investigative	[93]
MR-1029	DMS7FC6	Discovery agent	N.A.	Investigative	[147]
MR-1526	DM5WMXJ	Discovery agent	N.A.	Investigative	[147]
MR-2034	DMF04AG	Discovery agent	N.A.	Investigative	[137]
MR-2266	DMXWSIU	Discovery agent	N.A.	Investigative	[147]
N-(17-Methylmorphinan-3-yl)-N'-phenylurea	DMFRQ2U	Discovery agent	N.A.	Investigative	[65]
N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea	DMHANU5	Discovery agent	N.A.	Investigative	[65]
N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2	DMFNCQ1	Discovery agent	N.A.	Investigative	[148]
N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2	DM8QTSU	Discovery agent	N.A.	Investigative	[148]
N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2	DMSC9FV	Discovery agent	N.A.	Investigative	[148]
N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine	DM7SEM1	Discovery agent	N.A.	Investigative	[65]
N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine	DMLP9VM	Discovery agent	N.A.	Investigative	[65]
N-isobutylnoroxymorphone	DMN1FIU	Discovery agent	N.A.	Investigative	[149]
NalBzOH	DM0CP36	Discovery agent	N.A.	Investigative	[90]
naloxonazine	DM8ZMNH	Discovery agent	N.A.	Investigative	[95]
Naltrexone-6-alpha-ol	DMRAN5O	Discovery agent	N.A.	Investigative	[137]
naltriben	DMNDOLZ	Discovery agent	N.A.	Investigative	[19]
NCT-400	DM09UFT	Major depressive disorder	6A70.3	Investigative	[19]
NE-2	DMILP0F	Pain	MG30-MG3Z	Investigative	[19]
NORBINALTORPHIMINE	DMLYZOG	Discovery agent	N.A.	Investigative	[150]
normorphine	DMYQGFJ	Discovery agent	N.A.	Investigative	[19]
NRP290	DMC9XJA	Pain	MG30-MG3Z	Investigative	[19]
NRT-300	DM3IWP5	Pain	MG30-MG3Z	Investigative	[19]
O-DESMETHYL TRAMADOL	DM8ZG2I	Discovery agent	N.A.	Investigative	[137]
ORIPAVINE	DMPQGUL	Discovery agent	N.A.	Investigative	[93]
OXYMORPHINDOLE	DMTP4S2	Discovery agent	N.A.	Investigative	[114]
Oxymorphone semicarbazone hydrochloride	DMTSM61	Discovery agent	N.A.	Investigative	[109]
PHENAZOCINE	DMCTVMI	Discovery agent	N.A.	Investigative	[137]
PL017	DMICVXN	Discovery agent	N.A.	Investigative	[94]
PTI-601	DMQUSXK	Pain	MG30-MG3Z	Investigative	[19]
quadazocine	DM2Q6JY	Discovery agent	N.A.	Investigative	[19]
RTI-5989-31	DMZO1QC	Discovery agent	N.A.	Investigative	[151]
SB-0304	DMOZX0D	Discovery agent	N.A.	Investigative	[152]
Semorphone	DM1C5GZ	Discovery agent	N.A.	Investigative	[153]
SL-3111	DM0UE28	Discovery agent	N.A.	Investigative	[154]
SN-11	DMA0JZM	Discovery agent	N.A.	Investigative	[53]
SN-23	DM6O0PD	Discovery agent	N.A.	Investigative	[53]
SN-28	DMB8TJC	Discovery agent	N.A.	Investigative	[155]
SOMATOSTATIN	DMIOFQE	Acromegaly	5A60.0	Investigative	[97]
SPIROINDANYLOXYMORPHONE	DMNJVZU	Discovery agent	N.A.	Investigative	[156]
THEBAINE	DMRCD3O	Discovery agent	N.A.	Investigative	[93]
TQ-1017	DMEF32D	Pain	MG30-MG3Z	Investigative	[157]
Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	DMBU4KJ	Discovery agent	N.A.	Investigative	[92]
Tyr-(NMe)Ala-L-Phe-D-Pro-NH2	DMIWPKB	Discovery agent	N.A.	Investigative	[158]
Tyr-(R)-Aba-Gly-Phe-NH2	DMDQJUO	Discovery agent	N.A.	Investigative	[159]
Tyr-(R)-spiro-Aba-Gly-Phe-NH2	DMHNM3K	Discovery agent	N.A.	Investigative	[159]
Tyr-(S)-Aba-Gly-Phe-NH2	DMYZ792	Discovery agent	N.A.	Investigative	[159]
Tyr-(S)-spiro-Aba-Gly-Phe-NH2	DMT316S	Discovery agent	N.A.	Investigative	[159]
Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2	DM0D1Z5	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2	DMPH1G0	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Ala-Gly-NMePhe	DM2XRZL	Discovery agent	N.A.	Investigative	[87]
Tyr-D-Ala-Gly-Phe-Met-NH2	DMC7LND	Discovery agent	N.A.	Investigative	[51]
Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl	DMWOP9N	Discovery agent	N.A.	Investigative	[160]
Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc	DMB2TCF	Discovery agent	N.A.	Investigative	[133]
Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2	DMUXMVQ	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2	DMREJ69	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2	DMTPLNZ	Discovery agent	N.A.	Investigative	[161]
Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2	DMC4NO5	Discovery agent	N.A.	Investigative	[162]
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2	DM4FASR	Discovery agent	N.A.	Investigative	[161]
Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2	DMB9A46	Discovery agent	N.A.	Investigative	[161]
Tyr-D-Ala-Phe-Thr[-D-Glc(OAc)4]-Tyr-Pro-Ser-NH2	DMLC0NW	Discovery agent	N.A.	Investigative	[161]
Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2	DM4YTFP	Discovery agent	N.A.	Investigative	[162]
Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2	DMY9NIJ	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2	DMQREP2	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2	DMZ24LN	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2	DMPSJ72	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2	DMIWMN6	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2	DM2CEWT	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2	DMKM81A	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2	DMZOTGM	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2	DMM9H07	Discovery agent	N.A.	Investigative	[54]
Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2	DMN7290	Discovery agent	N.A.	Investigative	[54]
Tyr-Pro-3,5Dmp-Phe-NH2	DMDCJWU	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-D-(NMe)Phe-D-Pro-NH2	DMH08O3	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-D-Phe-D-Pro-NH2	DM4ZJR5	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-D-Phe-Pro-NH2	DMCTSNE	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-D-Phg-Phe-NH2	DMEDVRN	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Dmp-Phe-NH2	DMNXCHT	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-Dmt-Phe-NH2	DMOU43H	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-Emp-Phe-NH2	DMUKE43	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-Hfe-Phe-NH2	DME5HIS	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Hfe-Pro-NH2	DMJBR75	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Imp-Phe-NH2	DMUV3ZW	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-L-(NMe)Phe-D-Pro-NH2	DMI65GV	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-L-(NMe)Phe-Pro-NH2	DM1NITL	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-L-Phe-D-Pro-NH2	DMUVHGS	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-L-Phe-Pro-NH2	DM8VW3Z	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-Mmp-Phe-NH	DMRE7G3	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-Phe-Ala-Bn	DMIE4U5	Discovery agent	N.A.	Investigative	[164]
Tyr-Pro-Phe-D-2-Nal-NH2	DMLQ3PR	Discovery agent	N.A.	Investigative	[108]
Tyr-Pro-Phe-D-Ala-Bn	DMLEUF6	Discovery agent	N.A.	Investigative	[164]
Tyr-Pro-Phe-D-Phg-NH2	DM6YRVT	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Phe-D-Val-Bn	DM1QZ9X	Discovery agent	N.A.	Investigative	[164]
Tyr-Pro-Phe-Hfe-NH2	DM71P2O	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Phe-Phe-N(CH3)2	DM5DRIZ	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-NHCH3	DM2U4VI	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-NHNH2	DMY6V9R	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-OC(CH3)3	DMS4P1E	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-OCH2CH3	DMZNHEC	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-OCH2OH	DMFV7NI	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-OCH3	DMRQXHO	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phg-NH2	DM70HYT	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Phg-Phe-NH2	DMVDM73	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Phg-Pro-NH2	DMSGMPU	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Tmp-Phe-NH	DMR3IVB	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-Trp-D-Ala-Bn	DMFIPXA	Discovery agent	N.A.	Investigative	[164]
Tyr-Pro-Trp-D-Val-Bn	DMY5HX6	Discovery agent	N.A.	Investigative	[164]
Tyr-Pro-Trp-Gly-Bn	DMKLDWF	Discovery agent	N.A.	Investigative	[164]
Tyr-Sar-Phe-D-2-Nal-NH2	DMIZB25	Discovery agent	N.A.	Investigative	[108]
UFP-502	DMD8BRG	Discovery agent	N.A.	Investigative	[102]
UFP-512	DMYPVSJ	Discovery agent	N.A.	Investigative	[102]
YAWF-NH2	DMUW4KG	Discovery agent	N.A.	Investigative	[82]
YGGWL-NH2	DM5LYKW	Discovery agent	N.A.	Investigative	[82]
YGWFL-NH2	DMQ2EYJ	Discovery agent	N.A.	Investigative	[82]
YPAA-NH2	DMC3DK5	Discovery agent	N.A.	Investigative	[82]
YPWA-NH2	DMOTHAC	Discovery agent	N.A.	Investigative	[82]
YRFB	DMXOJIB	Discovery agent	N.A.	Investigative	[81]
ZYKLOPHIN	DM0S5PE	Discovery agent	N.A.	Investigative	[135]
[3H]diprenorphine	DMBMS1U	Discovery agent	N.A.	Investigative	[95]
[3H]U69593	DM6RSZ9	Discovery agent	N.A.	Investigative	[90]
[D-Ala2]Met-enkephalinamide	DM18ZNJ	Discovery agent	N.A.	Investigative	[146]
[Dcp1]Dyn A(1-11)-NH2	DM23GCK	Discovery agent	N.A.	Investigative	[100]
[Leu5]enkephalin	DMA0N32	Discovery agent	N.A.	Investigative	[166]
[Tyr-Pro-Phe-NH-CH2-]2	DMZTRQ0	Discovery agent	N.A.	Investigative	[167]
[Tyr-Pro-Phe-NH-]2	DM61RG2	Discovery agent	N.A.	Investigative	[167]
[Tyr-Pro-Phe-Phe-NH-CH2-]2	DMFGO4W	Discovery agent	N.A.	Investigative	[167]
[Tyr-Pro-Phe-Phe-NH-]2	DME6TNL	Discovery agent	N.A.	Investigative	[167]

References

• [1] Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
• [2] Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77.
• [3] Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
• [6] Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.
• [7] Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
• [8] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [9] Clinical pipeline report, company report or official report of kempharm.
• [10] Clinical pipeline report, company report or official report of signaturerx.
• [11] Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.
• [12] Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol. 1981 Jul 10;72(4):343-9.
• [13] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [14] Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
• [15] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [16] Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
• [17] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [18] OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
• [20] Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78.
• [21] The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevent... Pain. 2009 Jan;141(1-2):88-96.
• [22] Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth. 2015 Mar;114(3):364-6.
• [23] Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
• [24] A Review of Abuse-Deterrent Opioids For Chronic Nonmalignant Pain. P T. 2012 July; 37(7): 412-418.
• [25] Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94.
• [26] Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
• [27] Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
• [28] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [29] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [30] The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91.
• [31] Endomorphin-2: A Biased Agonist at the -Opioid Receptor. Mol Pharmacol. 2012 August; 82(2): 178-188.
• [32] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [33] US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same.
• [34] Synthesis and pharmacological evaluation of 1,2-dihydrospiro[isoquinoline-4(3H),4'-piperidin]-3-ones as nociceptin receptor agonists. J Med Chem. 2008 Feb 28;51(4):1058-62.
• [35] Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31.
• [36] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [37] Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56.
• [38] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009073)
• [39] DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function. J Pharmacol Exp Ther. 2003 Dec;307(3):1227-33.
• [40] Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3667-71.
• [41] A novel molecule (frakefamide) with peripheral opioid properties: the effects on resting ventilation compared with morphine and placebo. Anesth Analg. 2005 Mar;100(3):713-7, table of contents.
• [42] Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. J Pharmacol Exp Ther. 1991 Aug;258(2):502-10.
• [43] [3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol. 1983 Feb 18;87(2-3):209-25.
• [44] Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. Clin Pharmacol Ther. 1994 Sep;56(3):261-71.
• [45] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026307)
• [46] WO patent application no. 2007,0677,14, Treatment of sequelae of psychiatric disorders.
• [47] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [48] Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
• [49] Inhibition of cholinergic neurotransmission in human airways by opioids. J Appl Physiol (1985). 1992 Mar;72(3):1096-100.
• [50] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003724)
• [51] Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing tw... J Med Chem. 2010 Aug 12;53(15):5491-501.
• [52] The effects on resting ventilation of intravenous infusions of morphine or sameridine, a novel molecule with both local anesthetic and opioid properties. Anesth Analg. 1999 Jan;88(1):160-5.
• [53] Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
• [54] Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
• [55] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
• [56] Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4.
• [57] Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
• [58] 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8.
• [59] Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
• [60] Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
• [61] Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
• [62] The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23.
• [63] Discovery of novel triazole-based opioid receptor antagonists. J Med Chem. 2006 Jul 13;49(14):4044-7.
• [64] 14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7.
• [65] Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
• [66] Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorp... J Med Chem. 2006 Aug 24;49(17):5333-8.
• [67] Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic ... Bioorg Med Chem. 2009 Aug 15;17(16):5782-90.
• [68] 3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8.
• [69] Phenylmorphans and analogues: opioid receptor subtype selectivity and effect of conformation on activity. J Med Chem. 1992 May 1;35(9):1521-5.
• [70] Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM: Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000 Feb 10;43(3):381-91.
• [71] You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83.
• [72] Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
• [73] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [74] Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
• [75] Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
• [76] Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6.
• [77] Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4.
• [78] SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10.
• [79] Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-c... Bioorg Med Chem. 2008 May 15;16(10):5653-64.
• [80] Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
• [81] Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
• [82] Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6.
• [83] Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4946-50.
• [84] Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70.
• [85] Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
• [86] Beta-endorphin is a potent inhibitor of thymidine incorporation into DNA via mu- and kappa-opioid receptors in fetal rat brain cell aggregates in culture. J Neurochem. 1993 Feb;60(2):765-7.
• [87] Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors. J Med Chem. 2009 Dec 10;52(23):7372-5.
• [88] Electrophilic alpha-methylene-gamma-lactone and isothiocyanate opioid ligands related to etorphine. J Med Chem. 1990 Aug;33(8):2286-96.
• [89] Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22.
• [90] Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
• [91] Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem. 2007 Nov 1;50(22):5528-32.
• [92] Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
• [93] Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. J Biol Chem. 2007 Sep 14;282(37):27126-32.
• [94] Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J Pharmacol Exp Ther. 1983 Nov;227(2):403-8.
• [95] Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994 Feb;45(2):330-4.
• [96] Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonis... J Med Chem. 2004 Jun 3;47(12):3242-7.
• [97] Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
• [98] Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokini... J Med Chem. 2007 Jun 14;50(12):2779-86.
• [99] Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82.
• [100] Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
• [101] Synthesis and structure-activity relationships of deltorphin analogues. J Med Chem. 1991 May;34(5):1656-61.
• [102] Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30.
• [103] Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
• [104] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [105] [6-O-methyl-11C]Diprenorphine Molecular Imaging and Contrast Agent Database (MICAD) [Internet].
• [106] Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
• [107] Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20.
• [108] Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3.
• [109] Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5.
• [110] Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3.
• [111] Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2. Eur J Med Chem. 2010 Oct;45(10):4594-600.
• [112] Synthesis and evaluation of new endomorphin analogues modified at the Pro(2) residue. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4115-8.
• [113] Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol. 1995 Jun;39(6):611-20.
• [114] Ligand binding to nucleic acids and proteins: Does selectivity increase with strength Eur J Med Chem. 2008 Nov;43(11):2307-15.
• [115] Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus. Neuroscience. 2001;108(3):467-77.
• [116] Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23.
• [117] Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5275-9.
• [118] Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5.
• [119] Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80.
• [120] New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3.
• [121] From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005 Aug 25;48(17):5608-11.
• [122] Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
• [123] Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
• [124] Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem. 2004 Dec 16;47(26):6541-6.
• [125] Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
• [126] New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20.
• [127] Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
• [128] A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem. 2007 Nov 15;15(22):6876-81.
• [129] Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
• [130] Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem. 1991 Oct;34(10):3125-32.
• [131] Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors. J Med Chem. 1993 Nov 26;36(24):3748-56.
• [132] A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
• [133] Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
• [134] Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
• [135] The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21.
• [136] Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide. J Med Chem. 1994 Sep 2;37(18):2856-64.
• [137] Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
• [138] Investigation of Beckett-Casy model 1: synthesis of novel 16,17-seco-naltrexone derivatives and their pharmacology. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1055-8.
• [139] Potential affinity labels for the opiate receptor based on fentanyl and related compounds. J Med Chem. 1982 Aug;25(8):913-9.
• [140] 14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid rece... J Med Chem. 2009 Nov 12;52(21):6926-30.
• [141] Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem. 2009 Dec 10;52(23):7389-96.
• [142] In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
• [143] Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9.
• [144] High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
• [145] New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3.
• [146] Synthesis and biological evaluation of a metazocine-containing enkephalinamide. Evidence for nonidentical roles of the tyramine moiety in opiates a... J Med Chem. 1982 Dec;25(12):1423-7.
• [147] Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44.
• [148] Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702.
• [149] Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4978-81.
• [150] Synthesis of pyrrolomorphinan derivatives as kappa opioid agonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5035-8.
• [151] Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an ... J Med Chem. 2007 Aug 9;50(16):3765-76.
• [152] Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J Med Chem. 2008 Apr 24;51(8):2571-4.
• [153] Respiratory effects and tolerability of Mr 2264 Cl.A new opiate partial agonist in comparison with morphine and placebo.Eur J Clin Pharmacol.1994;46(4):301-4.
• [154] Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selecti... J Med Chem. 1999 Dec 30;42(26):5359-68.
• [155] Design and synthesis of KNT-127, a -opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5.
• [156] Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normo... Bioorg Med Chem. 2009 Aug 15;17(16):5983-8.
• [157] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [158] A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
• [159] Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7.
• [160] The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokin... J Med Chem. 2008 Oct 23;51(20):6334-47.
• [161] Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52.
• [162] Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. J Med Chem. 1994 Jan 7;37(1):141-5.
• [163] Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
• [164] Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91.
• [165] Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
• [166] Carba-analogues of fentanyl are opioid receptor agonists. J Med Chem. 2010 Apr 8;53(7):2875-81.
• [167] Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50.